- This morning, StemCells, Inc. (NASDAQ:STEM) released six-month interim results for the first group of patients in its Phase I/II trial, testing the company’s HuCNS-SC (human … Continue Reading
Read nowLong Ideas - Since reporting 2Q earnings on August 2nd, Threshold Pharmaceuticals (NASDAQ:THLD) gained 25% and is on track to end the month around $8.70, a $.50 premium … Continue Reading
Read nowQuick Picks - The Australian diagnostics company Genetic Technologies (NASDAQ:GENE)(ASX:GTG) is giving up gains from Wednesday, down 6% on the day to $3.48. The middle of the week … Continue Reading
Read nowLong Ideas - In a press release after the markets closed on Thursday, Achillion Pharmaceuticals (NASDAQ:ACHN) announced that the company will be selling $41.8M in common stock to … Continue Reading
Read now